These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38646787)

  • 1. Differential metabolic secretion between muscular dystrophy mouse-derived spindle cell sarcomas and rhabdomyosarcomas drives tumor type development.
    Niba ETE; Awano H; Nishimura N; Koide H; Matsuo M; Shinohara M
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C34-C47. PubMed ID: 38646787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heme Oxygenase-1 Influences Satellite Cells and Progression of Duchenne Muscular Dystrophy in Mice.
    Pietraszek-Gremplewicz K; Kozakowska M; Bronisz-Budzynska I; Ciesla M; Mucha O; Podkalicka P; Madej M; Glowniak U; Szade K; Stepniewski J; Jez M; Andrysiak K; Bukowska-Strakova K; Kaminska A; Kostera-Pruszczyk A; Jozkowicz A; Loboda A; Dulak J
    Antioxid Redox Signal; 2018 Jul; 29(2):128-148. PubMed ID: 29669436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pannexin 1 dysregulation in Duchenne muscular dystrophy and its exacerbation of dystrophic features in mdx mice.
    Freeman E; Langlois S; Leyba MF; Ammar T; Léger Z; McMillan HJ; Renaud JM; Jasmin BJ; Cowan KN
    Skelet Muscle; 2024 Apr; 14(1):8. PubMed ID: 38671506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
    Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
    EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
    Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
    Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why is early-onset atrial fibrillation uncommon in patients with Duchenne muscular dystrophy? Insights from the mdx mouse.
    Nguyen MN; Hooper C; Stefanini M; Vrellaku B; Carnicer R; Wood MJ; Simon JN; Casadei B
    Cardiovasc Res; 2024 Apr; 120(5):519-530. PubMed ID: 38270932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle.
    Lorena MDSV; Santos EKD; Ferretti R; Nagana Gowda GA; Odom GL; Chamberlain JS; Matsumura CY
    Skelet Muscle; 2023 Sep; 13(1):16. PubMed ID: 37705069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms and Consequences of Cerebellar Purkinje Cell Disinhibition in a Mouse Model of Duchenne Muscular Dystrophy.
    Wu WC; Bradley SP; Christie JM; Pugh JR
    J Neurosci; 2022 Mar; 42(10):2103-2115. PubMed ID: 35064002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
    Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
    Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice.
    Garbincius JF; Merz LE; Cuttitta AJ; Bayne KV; Schrade S; Armstead EA; Converso-Baran KL; Whitesall SE; D'Alecy LG; Michele DE
    Am J Physiol Heart Circ Physiol; 2020 Sep; 319(3):H582-H603. PubMed ID: 32762558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
    Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
    Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
    Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
    Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
    Terrill JR; Grounds MD; Arthur PG
    Int J Biochem Cell Biol; 2015 Sep; 66():141-8. PubMed ID: 26239309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing muscle contractility through low-frequency stimulation alters tibial bone geometry and reduces bone strength in
    Chan AS; Hardee JP; Blank M; Cho EH; McGregor NE; Sims NA; Lynch GS
    J Appl Physiol (1985); 2023 Jul; 135(1):77-87. PubMed ID: 37262103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy.
    Nitahara-Kasahara Y; Nakayama S; Kimura K; Yamaguchi S; Kakiuchi Y; Nito C; Hayashi M; Nakaishi T; Ueda Y; Okada T
    Stem Cell Res Ther; 2023 Apr; 14(1):108. PubMed ID: 37106393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy.
    Hammers DW; Hart CC; Matheny MK; Wright LA; Armellini M; Barton ER; Sweeney HL
    Sci Rep; 2020 Aug; 10(1):14070. PubMed ID: 32826942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
    Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
    Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.